137 related articles for article (PubMed ID: 16441824)
21. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
Bergua C; Torregrosa JV; Fuster D; Gutierrez-Dalmau A; Oppenheimer F; Campistol JM
Transplantation; 2008 Aug; 86(3):413-7. PubMed ID: 18698244
[TBL] [Abstract][Full Text] [Related]
22. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism.
Bergua C; Torregrosa JV; Cofán F; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2254-5. PubMed ID: 17889155
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of cinacalcet HCl treatment after kidney transplantation.
Copley JB; Germain M; Stern L; Pankewycz O; Katznelson S; Shah T; Wang O; Turner SA; Sprague SM
Transplant Proc; 2010 Sep; 42(7):2503-8. PubMed ID: 20832532
[TBL] [Abstract][Full Text] [Related]
24. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
Drüeke TB; Ritz E
Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
[TBL] [Abstract][Full Text] [Related]
25. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
[TBL] [Abstract][Full Text] [Related]
26. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
27. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with cinacalcet HCl.
Ureña Torres P
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
[TBL] [Abstract][Full Text] [Related]
29. [Calcimimetics].
Messa P; Como G; Brezzi B
G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
[TBL] [Abstract][Full Text] [Related]
30. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
[TBL] [Abstract][Full Text] [Related]
31. Drug Insight: renal indications of calcimimetics.
Shahapuni I; Monge M; Oprisiu R; Mazouz H; Westeel PF; Morinière P; Massy Z; Choukroun G; Fournier A
Nat Clin Pract Nephrol; 2006 Jun; 2(6):316-25. PubMed ID: 16932453
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR).
Brown EM
Biochem Pharmacol; 2010 Aug; 80(3):297-307. PubMed ID: 20382129
[TBL] [Abstract][Full Text] [Related]
33. Calcimimetics and calcilytics--fooling the calcium receptor.
Steddon SJ; Cunningham J
Lancet; 2005 Jun 25-Jul 1; 365(9478):2237-9. PubMed ID: 15978932
[TBL] [Abstract][Full Text] [Related]
34. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
[TBL] [Abstract][Full Text] [Related]
35. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism.
Szwarc I; Argilés A; Garrigue V; Delmas S; Chong G; Deleuze S; Mourad G
Transplantation; 2006 Sep; 82(5):675-80. PubMed ID: 16969292
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose.
Kamar N; Gennero I; Spataru L; Esposito L; Guitard J; Lavayssière L; Cointault O; Gandia P; Durand D; Rostaing L
Nephrol Dial Transplant; 2008 Nov; 23(11):3720-6. PubMed ID: 18558623
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
38. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
[TBL] [Abstract][Full Text] [Related]
39. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]